April 2006

Labopharm's Tramadol achieves pain reduction

Canadian pharmaceutical Labopharm has completed a late-stage Tramadol trial showing that the drug significantly reduced pain intensity in osteoarthritis patients over a 12 week period.

Results of the phase III clinical trial of tramadol (MDT3-005) will be added to the company's new drug application (NDA), which is currently under FDA review.

The randomized, multi-centre study compared the safety and efficacy of Labopharm's once-daily formulation of tramadol to placebo over a 12-week period. Enrollment in the trial consisted of patients diagnosed with moderate to severe pain associated with osteoarthritis of the knee. Approximately 1,000 patients were involved

To read more please visit..
http://www.pharmaceutical-business-review.com/article_news.asp?guid=4315E065-4F9C-4EE6-9397-5638B21FF846

Back to Tramadol News